GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hangzhou Tigermed Consulting Co Ltd (SZSE:300347) » Definitions » EV-to-EBIT

Hangzhou Tigermed Consulting Co (SZSE:300347) EV-to-EBIT : 16.48 (As of Apr. 27, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Hangzhou Tigermed Consulting Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Hangzhou Tigermed Consulting Co's Enterprise Value is ¥42,991 Mil. Hangzhou Tigermed Consulting Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ¥2,608 Mil. Therefore, Hangzhou Tigermed Consulting Co's EV-to-EBIT for today is 16.48.

The historical rank and industry rank for Hangzhou Tigermed Consulting Co's EV-to-EBIT or its related term are showing as below:

SZSE:300347' s EV-to-EBIT Range Over the Past 10 Years
Min: 12.5   Med: 49.41   Max: 115.49
Current: 15.02

During the past 13 years, the highest EV-to-EBIT of Hangzhou Tigermed Consulting Co was 115.49. The lowest was 12.50. And the median was 49.41.

SZSE:300347's EV-to-EBIT is ranked better than
65.42% of 107 companies
in the Medical Diagnostics & Research industry
Industry Median: 20.23 vs SZSE:300347: 15.02

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Hangzhou Tigermed Consulting Co's Enterprise Value for the quarter that ended in Dec. 2023 was ¥47,312 Mil. Hangzhou Tigermed Consulting Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ¥2,608 Mil. Hangzhou Tigermed Consulting Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 5.51%.


Hangzhou Tigermed Consulting Co EV-to-EBIT Historical Data

The historical data trend for Hangzhou Tigermed Consulting Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hangzhou Tigermed Consulting Co EV-to-EBIT Chart

Hangzhou Tigermed Consulting Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.21 58.60 28.74 33.52 18.14

Hangzhou Tigermed Consulting Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.52 31.00 19.52 21.83 18.14

Competitive Comparison of Hangzhou Tigermed Consulting Co's EV-to-EBIT

For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hangzhou Tigermed Consulting Co's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hangzhou Tigermed Consulting Co's EV-to-EBIT falls into.



Hangzhou Tigermed Consulting Co EV-to-EBIT Calculation

Hangzhou Tigermed Consulting Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=42990.871/2608.429
=16.48

Hangzhou Tigermed Consulting Co's current Enterprise Value is ¥42,991 Mil.
Hangzhou Tigermed Consulting Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,608 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hangzhou Tigermed Consulting Co  (SZSE:300347) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Hangzhou Tigermed Consulting Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=2608.429/47312.09546
=5.51 %

Hangzhou Tigermed Consulting Co's Enterprise Value for the quarter that ended in Dec. 2023 was ¥47,312 Mil.
Hangzhou Tigermed Consulting Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,608 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hangzhou Tigermed Consulting Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Hangzhou Tigermed Consulting Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Hangzhou Tigermed Consulting Co (SZSE:300347) Business Description

Traded in Other Exchanges
Address
Block 8, No. 19 Jugong Road, Room 2001-2010, 20th Floor, Xixing Sub-District, Binjiang District, Hangzhou, CHN, 310053
Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's segment includes Clinical trial solutions and Clinical-related and laboratory services. It generates maximum revenue from the Clinical trial solutions segment. The company's offered services include bioanalytical, medical writing, biostatistics analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.

Hangzhou Tigermed Consulting Co (SZSE:300347) Headlines

No Headlines